GMAT3:BMFBOVESPAGrupo Mateus SA Analysis
Data as of 2026-06-06 - not real-time
R$4.08
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Grupo Mateus is trading at R$4.08, comfortably below its 20‑day SMA of R$4.28 and well under the 50‑day (R$4.46) and 200‑day (R$5.41) averages, confirming a bearish technical backdrop. The RSI at 40 and a bearish MACD histogram reinforce downside pressure, while volume is trending lower, suggesting limited buying interest. Recent earnings disclosed a miss on both EPS and revenue forecasts for Q1 2026, adding short‑term disappointment to the price action. Despite the technical weakness, the stock appears dramatically undervalued: the DCF‑derived fair value of R$11.96 implies a potential upside of roughly 69 %. Fundamental ratios are attractive, with a trailing PE of 5.2, a price‑to‑book below 1, and a dividend yield of 6.11% supported by a modest payout ratio of 24%. The company generates solid operating cash flow and carries a manageable debt‑to‑equity of 55.8%, indicating capacity to sustain its dividend. Consumer‑cyclical exposure in Brazil adds medium‑level geographic and sector risk, but the low beta (~0.5‑0.85) tempers market volatility. Overall, the market’s extreme greed sentiment (Fear‑Greed Index 83) may be overlooking the disconnect between price and intrinsic value, creating a compelling entry point for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages and bearish MACD
- Recent earnings miss and decreasing volume
- High dividend yield provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap vs DCF fair value
- Attractive PE, PB and dividend yield
- Improving cash flow coverage of debt and dividend
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained undervaluation with upside potential >60%
- Stable dividend policy and low payout ratio
- Resilient fundamentals despite cyclical sector exposure
Key Metrics & Analysis
Financial Health
Revenue Growth12.90%
Profit Margin4.49%
P/E Ratio5.2
ROE16.01%
ROA6.03%
Debt/Equity55.78
P/B Ratio0.9
Op. Cash FlowR$2.1B
Free Cash FlowR$1.4B
Technical Analysis
TrendBearish
RSI40.4
SupportR$4.06
ResistanceR$4.64
MA 20R$4.28
MA 50R$4.46
MA 200R$5.41
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02
Valuation
Fair ValueR$11.96
Target PriceR$6.90
Upside/Downside69.12%
GradeUndervalued
TypeValue
Dividend Yield6.11%
Risk Assessment
Beta0.85
Volatility50.98%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.